Clovis Oncology Inc(CLVS) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Current Price

$5.67

RSI

47.280

Beta:

1.773303

February 25, 2021
31.6M
-48.3M

11.179 %
-30.700 %
-2.438 %
-2.152 %

$127,060,000
$137,002,000
$76,811,000
$43,722,000
$78,000
$0
-7.825 %
78.362 %
75.680 %
55953.846 %
0.000 %

$-369,759,000
$-398,626,000
$-367,401,000
$-349,975,000
$-381,171,000
$-381,937,000
7.807 %
-7.833 %
-4.743 %
8.914 %
0.201 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.